MetLife Investment Management LLC Decreases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

MetLife Investment Management LLC decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 53,327 shares of the biotechnology company’s stock after selling 575 shares during the period. MetLife Investment Management LLC owned approximately 0.06% of Sarepta Therapeutics worth $6,660,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Riggs Asset Managment Co. Inc. grew its stake in shares of Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 75 shares during the last quarter. CIBC Asset Management Inc increased its stake in Sarepta Therapeutics by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 86 shares during the period. EP Wealth Advisors LLC lifted its position in Sarepta Therapeutics by 2.1% in the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 103 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Sarepta Therapeutics by 1.9% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after purchasing an additional 120 shares during the period. Finally, Oppenheimer Asset Management Inc. grew its holdings in shares of Sarepta Therapeutics by 3.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock worth $557,000 after purchasing an additional 145 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Analyst Ratings Changes

SRPT has been the subject of several analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $182.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Jefferies Financial Group started coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They issued a “buy” rating and a $165.00 target price on the stock. Evercore ISI lowered their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Needham & Company LLC dropped their price objective on Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating for the company in a report on Wednesday. Finally, HC Wainwright began coverage on Sarepta Therapeutics in a research note on Monday, November 25th. They set a “sell” rating and a $80.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Trading Down 3.3 %

Shares of SRPT stock opened at $133.34 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 12-month low of $78.67 and a 12-month high of $173.25. The stock has a market capitalization of $12.74 billion, a P/E ratio of 106.67 and a beta of 0.81. The firm’s 50 day moving average is $122.37 and its 200 day moving average is $131.48.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.